Search

Background: It is necessary to develop novel, affordable, and accessible drugs with few side effects as alternatives of the currently available chemical agents for leishmaniasis. Objectives: The main purpose of this study was to evaluate the effects of these drugs on L. major under in vitro conditions. Materials and Methods: In the current study, 5, 10, 25, 50, and 100 µg/mL concentrations of aqueous extract of Artemisia sieberi and chemical artemisinin were tested on promastigotes of Leishmania major (L. major), uninfected macrophages, and infected macrophages with intracellular amastigotes of L. major, by direct counting and 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromid methods. Results: The results obtained for each drug were compared with other drugs and also with the results of the control groups. The results related to promastigote and amastigote assays showed that when the dose of both drugs increased, the parasite number is reduced in comparison with the control groups. Moreover, the parasitic burden in the test cultures decreased significantly. Macrophage assay results showed that the effects of both drugs on uninfected and healthy macrophages were very low. Conclusions: These results indicate that both drugs have anti-Leishmania effects, which was higher in Artemisia sieberi compared with artemisinin. Thus, carrying out further studies on the effects of Artemisia sieberi in infected animals with L. major is recommended.

Background: Visceral leishmaniasis is the most acute form of leishmaniasis. Instead of administering usual drugs with different side effects, applying a herbal drug can put forward a novel horizon in dealing with this parasite. Artemether is one of the derivatives of artemisinin, a new anti-malarial drug, and can be activated by heme to produce free radicals which, in turn, have toxic effect on the parasite. Objectives: In this study we used artemether as a new drug for treatment of visceral leishmaniasis. Materials and Methods: In the present study, BALB/c mice infected with Leishmania infantum (MHOM/TN/80/IPI1) were treated with the most effective dose of artemether assessed with In Vitro assay. Artemether was given in parenteral and oral forms. Parasite burdens in the spleen and liver were determined by homogenizing and counting the parasite rate and were compared with those in the untreated mice. To evaluate the apoptotic properties of artemether by FACS flowcytometry, annexin-V FLUOS staining was performe. Results: IC50 of the drug on Leishmania infantum was determined to be 25 μg/mL after 24 h. In Vivo experiments indicated that oral artemether treatment of mice, during 3 days and every 6 h (0.625 mg/kg) was more significant than parenteral (0.625 mg/kg IP) treatment. Artemether exerts its cytotoxic effect on this parasite via apoptosis-related mechanism. Accordingly, parasite burden in the current study decreased in the liver and spleen of mice by oral treatment. Conclusions: Artemether especially in oral treatment is an effective and simple method and may be used as a new method to treat visceral leishmaniasis.